Wellthy Therapeutics, a digital therapeutics company, has announced the appointment of Vasudev V. Tribhuvan as vice president, Partnerships & Alliances effective May 2018.

Vasudev’s previous role was at Biocon, where he was the senior director, marketing and led strategic initiatives for the metabolic unit while guiding the team on patient programmes. Prior to this he held sales and marketing leadership roles with AstraZeneca, Boehringer Ingelheim and Novo Nordisk. He is an alumni of the University of California, Los Angeles.

“We have reached a point where digital pills greatly augment conventional drugs to target outcomes which were previously unheard of. Our company has already been pioneering outcomes beyond the pill in India. Vasudev's experience in understanding healthcare stakeholder problems, coupled with our world-class platform has an incredible potential to accelerate our impact goals, both in India and Asia,” stated Abhishek Shah, Co-Founder and CEO, Wellthy Therapeutics.

Commenting on his new role, Vasudev V. Tribhuvan said, “For years, there has been a push within the pharmaceutical industry to move ‘beyond the pill’, to improve outcomes in chronic metabolic disorders. The impetus to move beyond the pill typically arises from the realizations that drugs alone do not suffice for patients to achieve optimal clinical outcomes. Pharma companies should consider integrating beyond-the-pill solutions as a differentiated package offering in chronic disease categories.”